We are live on ! Find out more

Talphera

TLPH

Market cap $60.7M

1.17 USD

+0.01

0.86%

At close Updated Sep 21, 4:00 PM EDT

Pre-market

After hours

1.07

-0.10

8.55%

1 day

0.86%

5 days

-5.65%

1 month

-1.68%

3 months

19.12%

6 months

46.03%

Year to date

0.86%

1 year

25.83%

5 years

-94.21%

10 years

-98.38%

About: Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Employees: 12

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 80%

Negative 0%

Zacks Investment Research

Talphera (TLPH) Upgraded to Buy: Here's What You Should Know

Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Talphera (TLPH) Upgraded to Buy: Here's What You Should Know

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SAN MATEO, Calif., Sept. 3, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Company management will be presenting at the H.C.

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion Cash and investments of $17.1 million at June 30, 2026 Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced financial results for the second quarter of 2026 and provided a corporate update on the development of nafamostat.

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m.

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript

Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript

Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial results and provided a corporate update.

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026, then host a live webcast and conference call at 4:30 p.m.

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026

SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the acceptance of two abstracts for presentation at the 31st Annual International Conference on Advances in Critical Care Nephrology: AKI & CRRT 2026 to be held March 29-April 2, 2026 in San Diego.

Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026

Talphera, Inc. (TLPH) Analyst/Investor Day Transcript

Talphera, Inc. (TLPH) Analyst/Investor Day Transcript

Talphera, Inc. (TLPH) Analyst/Investor Day Transcript

See News Rankings

Price charts implemented using Lightweight Charts™